I agree that it was more than likely a good deal for both parties. The plant in the building is more what they would have wanted. There tech albeit a different product to Cardiocel(but not that different) is using the very same that we need. There tech is based on knees only at this stage and uses as far as I can gather from the below link, Carticel tech patch
http://www.carticel.com/healthcare/clinical-evidence/star-study-research.aspx
I agree that it was more than likely a good deal for both...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.30 |
Change
0.250(1.31%) |
Mkt cap ! $370.9M | |||
| Open | High | Low | Value | Volume |
| $19.05 | $19.50 | $18.90 | $130.5K | 6.761K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 375 | $19.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.50 | 2353 | 3 |
View Market Depth
| Last trade - 16.10pm 12/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.39 |
Change
0.250 ( 2.05 %) |
||||
| Open | High | Low | Volume | ||
| $19.00 | $19.39 | $19.00 | 224 | ||
| Last updated 11.17am 12/06/2024 ? | |||||
| AVR (ASX) Chart |